| Literature DB >> 32326004 |
Wen-Ching Huang1, Yu-Tang Tung2, Mai-Szu Wu3,4,5, Ming-Che Liu6,7,8,9, Tsai-Jung Lin10, Ming-Ta Yang11.
Abstract
Low-osmolality carbohydrate-electrolyte solution (LCS) ingestion can replace losses from exercise-induced dehydration, but the benefits of LCS ingestion strategy after exhaustive endurance exercise (EEE) remain unknown. The present study evaluated the effects of LCS ingestion on dehydration, oxidative stress, renal function, and aerobic capacity after EEE. In our study with its double-blind, crossover, counterbalanced design, 12 healthy male participants were asked to consume LCS (150 mL four times per hour) or placebo (water) 1 h before and 1 h after EEE. All participants completed a graded exercise test to exhaustion on a treadmill for the determination of maximal oxygen consumption (VO2max), applied to further intensity calibration, and then completed the EEE test. The average heart rate, maximal heart rate, running time to exhaustion, and peak oxygen uptake (VO2peak) were recorded during the exercise period. The participants' body weight was recorded at different time points before and after the EEE to calculate the dehydration rate. Blood samples were drawn at baseline and before, immediately after, 1 h after, and 2 h after EEE to determine indicators of oxidative stress and renal function. The results indicated that the dehydration rates in participants with LCS ingestion at 15 min, 30 min, and 45 min after EEE were significantly lower than in participants with placebo ingestion (-1.86 ± 0.47% vs. -2.24 ± 0.72%; -1.78 ± 0.50% vs. -2.13 ± 0.74%; -1.54 ± 0.51% vs. -1.94 ± 0.72%, respectively; p < 0.05). In addition, the concentration of catalase in participants with LCS ingestion immediately after EEE was significantly higher than in participants with placebo ingestion (2046.21 ± 381.98 nmol/min/mL vs. 1820.37 ± 417.35 nmol/min/mL; p < 0.05). Moreover, the concentration of protein carbonyl in participants with LCS ingestion immediately after EEE was slightly lower than in participants with placebo ingestion (2.72 ± 0.31 nmol carbonyl/mg protein vs. 2.89 ± 0.43 nmol carbonyl/mg protein; p = 0.06). No differences were noted for other variables. Our findings conclude that LCS ingestion can effectively avoid fluid loss and oxidative stress after EEE. However, LCS ingestion had no benefits for renal function or aerobic capacity.Entities:
Keywords: antioxidation; dehydration; exhaustive endurance exercise; oxidative stress; rehydration solution
Year: 2020 PMID: 32326004 PMCID: PMC7222420 DOI: 10.3390/antiox9040336
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Figure 1Experimental scheme. The experiment was based on a crossover double-blind design. The participants engaged in the treadmill exercise for 60 min with 70% maximal oxygen consumption () intensity, followed by 90% until exhaustion. The indicated fluid was ingested at a rate of 600 mL/h (150 mL/15 min) before and after exhaustive endurance exercise. The participants’ BW information and blood samples were collected at indicated time points. LCS, low-osmolality carbohydrate–electrolyte solution; Pre, Pre-exercise; Post-0, Immediately after exercise; Post-60, 60 min after exercise; Post-120, 120 min after exercise.
Figure 2Changes in dehydration rate after exhaustive endurance exercise. The dehydration rate was calculated using difference ratios compared with baseline body weight at the indicated time points (45, 30, and 15 min) after exhaustive endurance exercise. #Significant (p < 0.05) difference between conditions. LCS, low-osmolality carbohydrate–electrolyte solution; Post-15, 15 min after exercise; Post-30, 30 min after exercise; Post-45, 45 min after exercise; Post-60, 60 min after exercise.
Figure 3Changes in (A) creatinine and (B) estimated glomerular filtration rate (eGFR) after exhaustive endurance exercise. * Significant (p < 0.05) difference from baseline. LCS, low-osmolality carbohydrate–electrolyte solution; Pre, Pre-exercise; Post-0, Immediately after exercise; Post-60, 60 min after exercise; Post-120, 120 min after exercise.
Changes in electrolytes and osmolality after exhaustive endurance exercise.
| Parameters | Baseline | Pre | Post-0 | Post-60 | Post-120 |
|---|---|---|---|---|---|
| Na+ (mmol/L) | |||||
| LCS | 140.25 ± 0.75 | 140.50 ± 0.67 * | 143.50 ± 1.83 *,‡
| 141.67 ± 1.44 *,‡,+ | 141.25 ± 1.77 *,+ |
| Placebo | 140.50 ± 1.68 | 140.58 ± 1.17 | 143.92 ± 1.88 *,‡ | 141.17 ± 1.27 ‡,+ | 140.75 ± 1.42 +,† |
| Cl− (mmol/L) | |||||
| LCS | 102.17 ± 1.64 | 102.92 ± 1.98 * | 104.50 ± 1.68 *,‡,# | 103.00 ± 1.76 + | 102.67 ± 1.50 + |
| Placebo | 103.25 ± 1.48 | 103.83 ± 1.40 | 105.92 ± 1.31 *,‡ | 103.42 ± 1.68 + | 103.33 ± 1.92 + |
| K+ (mmol/L) | |||||
| LCS | 3.97 ± 0.28 | 4.07 ± 0.27 * | 4.26 ± 0.35 * | 4.70 ± 0.49 *,‡,+ | 4.50 ± 0.35 *,‡,† |
| Placebo | 4.08 ± 0.26 | 4.17 ± 0.30 | 4.30 ± 0.37 * | 4.63 ± 0.40 *,‡,+ | 4.33 ± 0.43 † |
| O (mOsm/L) | |||||
| LCS | 291.33 ± 2.10 | 289.67 ± 2.50 * | 299.58 ± 5.92 *, ‡ | 292.92 ± 3.87 ‡,+ | 292.17 ± 4.34 + |
| Placebo | 291.92 ± 3.15 | 290.33 ± 2.15 * | 301.00 ± 5.36 *,‡ | 291.75 ± 2.30 + | 290.25 ± 2.45 +,† |
Data are presented as mean ± standard deviation (coefficient of variation) (n = 12). The LCS and placebo were ingested twice: after baseline and at the Post-15 time point. The difference was considered significant when p was < 0.05. * Significant (p < 0.05) difference from the baseline. ‡ Significant (p < 0.05) difference from Pre. + Significant (p < 0.05) difference from Post-0. † Significant (p < 0.05) difference from the Post-60. # Significant (p < 0.05) difference between treatments. LCS, low-osmolality carbohydrate-electrolyte solution; Na+, sodium; Cl−, chlorine; K+, potassium; O, osmolality; Pre, pre-exercise; Post-0, immediately after exercise; Post-60, 60 min after exercise; Post-120, 120 min after exercise.
Changes in electrolytes and osmolality of urine after exhaustive endurance exercise.
| Parameters | Pre-U | Post-U |
|---|---|---|
| Na+ (mmol/L) | ||
| LCS | 41.71 ± 14.95 (35.84%) | 62.00 ± 47.22 (76.17%) |
| Placebo | 56.86 ± 24.35 (42.83%) | 60.29 ± 43.64 (72.39%) |
| Cl− (mmol/L) | ||
| LCS | 43.00 ± 12.94 (30.08%) | 63.43 ± 46.60 (73.46%) |
| Placebo | 61.43 ± 30.03 (48.89%) | 59.14 ± 37.03 (62.61%) |
| K− (mmol/L) | ||
| LCS | 10.54 ± 6.31 (59.83%) | 33.33 ± 13.96 * (41.87%) |
| Placebo | 15.60 ± 7.12 (45.63%) | 28.79 ± 16.01 (55.61%) |
| O (mOsm/L) | ||
| LCS | 294.43 ± 141.49 # (48.06%) | 350.10 ± 212.31 (60.64%) |
| Placebo | 349.43 ± 127.07 (36.36%) | 361.00 ± 230.49 (63.85) |
The data are presented mean ± standard deviation (coefficient of variation) (n = 7). Pre-U and Post-U represent the urine collection period during LCS and placebo ingestion before and after exhaustive endurance exercise. * Significant (p < 0.05) difference from Pre-U. # Significant (p < 0.05) difference between conditions. LCS, low-osmolality carbohydrate–electrolyte solution; Na+, sodium; Cl−, chlorine; K+, potassium; O, osmolality; Pre-U, pre-exercise urine measurement; Post-U, post-exercise urine measurement.
Changes in oxidative stress, antioxidative capacity, and inflammation after exhaustive endurance exercise.
| Parameters | Baseline | Pre | Post-0 | Post-60 | Post-120 |
|---|---|---|---|---|---|
| TBARS (µM) | |||||
| LCS | 2.73 ± 0.52 | 2.79 ± 0.50 | 2.95 ± 0.70 | 2.68 ± 0.57 | 2.89 ± 0.54 |
| Placebo | 2.73 ± 0.44 | 2.85 ± 0.61 | 2.93 ± 0.49 | 2.88 ± 0.66 | 2.97 ± 0.60 |
| PC (nmol carbonyl/mg protein) | |||||
| LCS | 3.02 ± 0.58 | 2.87 ± 0.37 | 2.72 ± 0.31 *,# | 2.89 ± 0.52 | 2.77 ± 0.31 * |
| Placebo | 3.08 ± 0.67 | 3.01 ± 0.50 | 2.89 ± 0.43 | 2.89 ± 0.46 | 3.03 ± 0.98 |
| GPx (U) | |||||
| LCS | 1076.30 ± 180.54 | 1249.87 ± 195.95 | 1239.71 ± 275.29 | 1226.17 ± 256.26 | 1289.97 ± 214.49 |
| Placebo | 1270.44 ± 237.65 | 1313.28 ± 295.39 | 1364.84 ± 301.27 | 1347.40 ± 251.12 | 1274.61 ± 290.00 |
| SOD (U/mL) | |||||
| LCS | 5.18 ± 0.80 | 5.43 ± 0.56 | 6.15 ± 0.89 *,‡ | 5.94 ± 0.89 *,‡ | 6.02 ± 1.00 *,‡ |
| Placebo | 5.34 ± 0.51 | 5.40 ± 0.63 | 5.78 ± 0.78 | 5.95 ± 1.30 | 5.60 ± 0.56 |
| CAT (nmol/min/mL) | |||||
| LCS | 1270.56 ± 246.95 | 1340.99 ± 266.67 | 2046.21 ± 381.98 *,‡,# | 1565.47 ± 367.23 *,‡,+ | 1677.25 ± 395.63 *,‡,+ |
| Placebo | 1337.18 ± 386.32 | 1471.97 ± 302.45 | 1820.37 ± 417.35 *,‡ | 1623.01 ± 443.46 | 1694.80 ± 419.63 *,‡ |
| CRP (mg/dL) | |||||
| LCS | 0.06 ± 0.06 | 0.06 ± 0.06 | 0.07 ± 0.06 *,‡ | 0.06 ± 0.06 + | 0.06 ± 0.06 + |
| Placebo | 0.08 ± 0.13 | 0.08 ± 0.13 | 0.09 ± 0.14 | 0.08 ± 0.13 | 0.08 ± 0.14 |
The data are presented as mean ± standard deviation (coefficient of variation) (n = 12). LCS and placebo were ingested twice: after baseline and immediately after exercise. The difference was considered significant when p was < 0.05. * Significant (p < 0.05) difference from baseline. ‡ Significant (p < 0.05) difference from Pre. + Significant (p < 0.05) difference from Post-0. # Significant (p < 0.05) difference between treatments. LCS, low-osmolality carbohydrate–electrolyte solution; TBARS, thiobarbituric acid reactive substances; PC, protein carbonyl; GPx, glutathione peroxidase; SOD, superoxide dismutase; CAT, catalase; CRP, C-reactive protein; Pre, pre-exercise; Post-0, Immediately after exercise; Post-60, 60 min after exercise; Post-120, 120 min after exercise.
Changes in aerobic capacity after exhaustive endurance exercise.
| Parameters | Exhaustion (min) | MHR (beats/min) | |
|---|---|---|---|
| LCS | 63.13 ± 3.35 (5.30%) | 198.58 ± 9.97 (5.02%) | 52.33 ± 6.66 (12.72%) |
| Placebo | 63.28 ± 3.37 (5.33%) | 198.00 ± 9.49 (4.79%) | 53.11 ± 6.44 (12.13%) |
The data are presented as mean ± standard deviation (coefficient of variation) (n = 12). Time until exhaustion was recorded for running at 90% immediately after 60 min of exercise at 70% . LCS, low-osmolality carbohydrate–electrolyte solution; MHR, maximal heart rate; , peak oxygen intake.